For years, the test for a legal CBD oil in Greece was a single number: how much THC it contained. Stay under the hemp threshold and the bottle could go on the shelf. Since September 2026 that number no longer settles the question. What matters now is what else is in the bottle besides cannabidiol, and because a plant extract is never one substance, full-spectrum and broad-spectrum CBD products have been pushed out of the legal market without the law ever using those words.
This article starts from a report published by the German trade outlet Hanf Magazin on 4 October 2026 on a circular issued by the Greek Ministry of Health on 15 September 2026. The circular tells inspectors and retailers how to apply cannabis rules that were tightened over the summer. Their foundation is Law 5302/2026, published in the Greek Government Gazette on 20 May 2026. We use the Greek case as a reference point for a wider question: what does EU law actually say about CBD, where do member states have room to restrict it, and how does the Greek approach compare with what Washington and London are doing to the same products?
Key Takeaways
Greece narrowed its CBD market in two steps. Law 5302/2026, passed in May, bans the retail sale of dried hemp flower to consumers even when it contains no more than 0.3 percent THC, and confines sales of cannabis products to licensed specialist shops and pharmacies. In July, according to consistent trade-press reports, the definition of a permitted product was rewritten: it now covers qualifying cosmetics and food supplements plus a separate category of products containing “exclusively cannabidiol.” The 15 September circular is the enforcement guidance for that definition. Full-spectrum extracts always contain other cannabinoids and traces of THC, and broad-spectrum extracts contain at least the other cannabinoids, so neither fits the new category. The EU’s top court ruled in 2020 that a member state may keep lawfully produced CBD from another member state off its market only if the restriction genuinely protects public health and is proportionate. No court has yet tested the Greek rule against that standard. One caveat governs everything below: we could not obtain the text of the circular itself. The account rests on press reports and on statements from a producer directly affected by the rule.
What the Greece Full-Spectrum CBD Ban Actually Says
There is no provision in Greek law headed “full-spectrum ban.” The effect comes from a definition. According to a 22 September 2026 report in NUG Magazine, the revised law recognises qualifying cosmetics and food supplements, along with a separate category of products that contain “exclusively cannabidiol (CBD).” Anything that fits none of those boxes is no longer a permitted cannabis product.
The earlier definition was much wider, and it can be read in the statute. Article 46 of Law 5302/2026 described permitted cannabis products as goods derived from hemp varieties with up to 0.3 percent THC “or products containing cannabidiol.” Foods as defined in EU law were carved out of that provision and left to food legislation. The entire change sits in the gap between “containing” and “exclusively containing.”
Hanf Magazin reports that the circular is addressed to enforcement bodies and businesses, describes how to identify prohibited products, and sets no transition period. Inspections are carried out on site by the national medicines agency EOF, with police support where needed. Under Article 51, a shop that breaches its licensing and operating conditions faces a fine of €100,000 and loses its operating licence for six months. For conduct beyond that, the article refers to the penalties of Greece’s narcotics statute, Law 4139/2013; Hanf Magazin puts the upper end at five years in prison.
From Flower Ban to “Exclusively CBD”: The Timeline
The tightening did not arrive overnight. In March 2025, the health and justice ministries issued a joint decision placing intoxicating semi-synthetic relatives of THC and CBD, such as H4CBD and THCP, under the narcotics law. Those compounds had been showing up in kiosks and vending machines, and they were the stated reason for the legislative package that followed.
A public consultation on the draft ran in April 2026. Law 5302/2026 took effect on 20 May. Article 43 raised the THC threshold for industrial hemp from 0.2 to 0.3 percent and, in the same breath, imposed a “universal” ban on retail sale of dried hemp flower and on its purchase and use by consumers. Import, storage and wholesale remain legal when the flower is destined exclusively for industrial processing, for example into cosmetics. Article 47 limits retail to licensed, registered specialist shops and pharmacies. The shops must stand at least 200 metres from secondary schools, and vending machines are prohibited.
Michalis Theodoropoulos, founder and chief executive of the organic hemp producer Kannabio, argued in a June guest commentary for HempToday that the law went far beyond its stated target and hit natural hemp products that “were never the primary source of the public health concerns cited by policymakers.” In July, by the accounts available, the definition was sharpened to “exclusively CBD.” None of the reports gives the number of that amending law.
Why Almost Every Plant Extract Fails the Test
Think of a hemp extract the way you would think of fresh orange juice. It is not just vitamin C; it is hundreds of accompanying compounds. In hemp, the most important ones are cannabinoids. A full-spectrum extract carries CBD together with cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), aroma compounds and traces of THC. In a broad-spectrum extract the THC is stripped out as far as possible while the other cannabinoids stay. Only an isolate is the separated pure substance. Our guide to CBD explains the molecule itself in more detail.
Kannabio says its full-spectrum extracts typically contain less than 0.2 percent THC, while broad-spectrum products can retain quantifiable traces below 0.05 percent. In the company’s reading, products containing THC now appear to be prohibited regardless of concentration. A Greek legal analysis cited by NUG Magazine reaches the same conclusion for broad-spectrum extracts and for products built around CBG: they contain cannabinoids other than CBD and therefore fall outside the definition.
How literally regulators will read “exclusively” is unresolved. Even highly purified plant-derived CBD can retain minute traces of other cannabinoids. Kannabio has said some formulations will have to change, with natural extracts replaced by isolate. Theodoropoulos told the trade press that “the Minister of Health is setting Greece back 15 years in terms of regulating the legal cannabis market,” and that the rule favours large medical cannabis companies over small hemp producers. That is the view of a party with a direct commercial stake. The reports we reviewed contain no response from the ministry.
Three Legal Lanes: How the EU Classifies CBD
The Greek case looks confusing because the EU has no single CBD law. A product is judged in one of several legal lanes, depending on how it is presented.
The first lane is drug law. In its Kanavape judgment of 19 November 2020, the Court of Justice held that CBD is not a narcotic within the meaning of the UN Single Convention. The familiar 0.3 percent THC figure comes from somewhere else entirely: agricultural law. Since 2023 it has been the threshold for hemp varieties eligible for support under the Common Agricultural Policy. It describes the plant in the field. There is no harmonised EU-wide THC limit for a finished bottle of CBD oil.
The second lane is food law. Cannabinoid extracts are classed as novel foods and need authorisation under Regulation (EU) 2015/2283 before they can be sold. To date, not one CBD food has been authorised in the EU. In February 2026 the European Food Safety Authority named a provisional safe intake level for the first time: 0.0275 milligrams of CBD per kilogram of body weight per day, about 2 milligrams for a 70-kilogram adult. That figure applies only to food supplements with CBD of at least 98 percent purity. In other words, it does not cover full-spectrum extracts at all. We unpacked the first product-specific opinions in our analysis of the EFSA safety assessment of CBD as a novel food.
The third lane is cosmetics. Creams and oils for external use fall under the EU Cosmetics Regulation and sit outside the novel food problem. Alongside all three runs medicines law, with Epidyolex as the authorised CBD medicine. Prescription cannabinoid medicines are untouched by the new Greek rule.
Seen this way, Athens has landed close to EFSA’s line: what is accepted is, in essence, the pure substance. The difference is the instrument. EFSA assesses individual applications on scientific evidence. Greece excludes an entire class of products by statutory definition.
Can the Rule Survive EU Law?
Kanavape supplies the test. A member state may restrict the sale of CBD lawfully produced in another EU country from the whole hemp plant only if the measure is suitable for protecting public health and does not go beyond what is necessary. The state has to show a real risk; a hypothesis is not enough.
Against the Greek rule stands the fact that it excludes products regardless of THC content, catching broad-spectrum extracts in which THC is barely measurable. In its favour, member states have latitude on health protection, and quality in this market does vary: a European laboratory analysis found that roughly half of CBD oils did not contain what their labels claimed, and 39 percent would have pushed a consumer past EFSA’s acute reference dose for THC at the recommended serving. How judges would weigh those points is an open question.
Only the route is clear. Either the European Commission opens infringement proceedings, or an affected company sues in a Greek court, which can refer the question to Luxembourg. Both take years, and national law applies in the meantime. Nor is Greece an outlier. Our comparison of CBD regulation across nine European countries shows Italy pulling hemp flower under narcotics law in 2025, the Netherlands tolerating consumer CBD only up to 0.05 percent THC, and Finland treating most CBD preparations as medicines. France offers the mirror image of Greece: it banned CBD edibles while leaving smokable flower on sale, whereas Athens has banned the flower and kept a lane open for isolate.
The Same Squeeze Elsewhere: 0.4 Milligrams in Washington, One Milligram in London
Readers outside the EU should not file this under foreign curiosities. The two largest English-speaking CBD markets are closing in on full-spectrum products by a different method that produces a similar result.
In the United States, the 2018 Farm Bill defined hemp by a single measure, 0.3 percent delta-9 THC by dry weight, and a retail market grew up inside that definition with no pre-market safety review. A federal spending law passed in autumn 2025 rewrote it. As summarised by attorneys at the law firm Dykema in September 2026, hemp must now stay within 0.3 percent total THC including THCA, cannabinoids synthesised outside the plant are excluded, and a finished product may hold no more than 0.4 milligrams of total THC per container. The change was due to take effect on 12 November 2026 and has been pushed to 11 December 2026 by a continuing resolution. A purely illustrative calculation shows what the cap means: a bottle holding 10 grams of oil at 0.1 percent THC contains 10 milligrams, twenty-five times the limit. Most full-spectrum oils cannot meet it without reformulation.
The United Kingdom got there earlier. Under the Misuse of Drugs Regulations 2001, a product containing a controlled drug such as THC is exempt only if, among other conditions, no component part contains more than one milligram of it, which is far below what a typical full-spectrum bottle carries. On the food side, the Food Standards Agency set a provisional acceptable daily intake of 10 milligrams of CBD in 2023, and its board agreed in September 2026 to recommend the first three CBD applications to ministers: one synthetic CBD and two hemp isolates. No full-spectrum extract is among them.
Three jurisdictions, three tools: a statutory definition in Athens, a per-container cap in Washington, a per-component limit and an authorisation queue in London. In each, the product that passes most easily is the isolate.
What the Reports Do Not Establish
The evidence has gaps, and they should be stated plainly. The 15 September circular is described in press reports but not documented word for word. The reading that THC is excluded at any concentration comes from Kannabio, a company that makes full-spectrum products. There are no figures on how many products or businesses are affected, and no reports yet of inspections or fines under the new definition.
The rule also says nothing about whether full-spectrum extracts are safe. It is a legal boundary, not a toxicological finding. Equally, industry criticism does not show that the rule breaches EU law. Only a court can decide that, and no such case has been reported.
FAQ
According to the interpretation that trade media and producers draw from the 15 September 2026 circular, it can no longer be sold, because the new product category must contain exclusively cannabidiol and a full-spectrum extract always contains other cannabinoids and traces of THC. No court has ruled on the question, and the wording of the circular has not been published in the reports available.
Full-spectrum is the whole-plant extract: CBD, other cannabinoids, aroma compounds and traces of THC. Broad-spectrum has had the THC largely removed while keeping the other cannabinoids. Isolate is purified CBD, usually at 98 percent or higher. Only the third matches the Greek formula of “exclusively CBD,” and even there it is unclear how regulators will treat residual traces.
In the United States it remains legal at federal level under the 2018 Farm Bill definition until the revised definition takes effect, currently scheduled for 11 December 2026; after that, a finished hemp product may contain no more than 0.4 milligrams of total THC per container, and state laws add their own restrictions. In the United Kingdom, a consumer product must meet the exempt-product conditions, including the one-milligram limit on controlled cannabinoids, and CBD foods must be linked to a novel food application. Neither country’s rules change what applies inside Greece, where anyone selling to Greek customers is subject to Greek law.
Not automatically. The Commission can open infringement proceedings, and affected businesses can sue in Greek courts, which may refer the matter to the Court of Justice. The benchmark would be the Kanavape ruling: a restriction must serve public health and be proportionate. Until a decision is reached, the national rule stays in force.
Legal Disclaimer
This article is a journalistic summary of published laws, court rulings and press reports. It is not legal or medical advice and does not recommend buying, using or selling any CBD product. The account of Greek law relies in part on third-party reporting and on statements from affected businesses; the text of the 15 September 2026 circular was not available to us. Laws on cannabinoids differ substantially between EU member states, the United Kingdom and the United States, including between individual US states, and they change frequently. CBD can interact with prescription medicines. Anyone who manufactures, sells or ships these products across borders should check the current rules in each country and seek qualified advice. For health questions, speak to a doctor or pharmacist.
